R
Rohit Gosain
Researcher at Roswell Park Cancer Institute
Publications - 24
Citations - 530
Rohit Gosain is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 7, co-authored 20 publications receiving 307 citations. Previous affiliations of Rohit Gosain include University at Buffalo.
Papers
More filters
Journal ArticleDOI
COVID-19 and Cancer: a Comprehensive Review.
TL;DR: This comprehensive review discusses the impact of COVID-19 on health and the immune system of those affected, reviewing the latest treatment approaches and ongoing clinical trials and proposes potential approaches to manage this vulnerable population during this pandemic.
Journal ArticleDOI
Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines.
TL;DR: The adjuvant management of lung NETs, as recommended by different guidelines, and their differences are described, including the use of peptide receptor radionucleotide therapy.
Journal ArticleDOI
Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment.
Madan Raj Aryal,Rohit Gosain,Anthony J. Donato,Ranjan Pathak,Vijaya Raj Bhatt,Anjan Katel,Peter A. Kouides +6 more
TL;DR: This article provides a framework that can guide clinicians in managing thrombotic complications in this challenging condition and proposes algorithms for screening, prevention, and treatment of severe hospitalized COVID-19 patients.
Journal ArticleDOI
Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment
Rahul Gosain,Amitoj Gill,Jacob Fuqua,Lesley H. Volz,Mika R. Kessans Knable,Ryan Bycroft,Sarah Seger,Rohit Gosain,Jorge A. Rios,Ju-Hsien Chao +9 more
TL;DR: With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the pro‐inflammatory surge and adverse side effects of medications such as carfilzomib and gemcitabine should be considered in the appropriate settings.
Journal ArticleDOI
Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world.
Madan Raj Aryal,Rohit Gosain,Anthony J. Donato,Han Yu,Anjan Katel,Yashoda Bhandari,Rashmi Dhital,Peter A. Kouides +7 more
TL;DR: Apixaban shows equivalent efficacy in prevention of recurrent VTE but decreased risk of major and minor bleeding events compared with rivaroxaban.